Rockwell Medical (NASDAQ:RMTI) Announces Earnings Results

Rockwell Medical (NASDAQ:RMTI) released its quarterly earnings data on Thursday. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04), Zacks reports. The business had revenue of $24.67 million during the quarter, compared to analysts’ expectations of $23.65 million. Rockwell Medical had a negative net margin of 1.25% and a positive return on equity of 8.55%. Rockwell Medical updated its FY 2025 guidance to EPS.

Rockwell Medical Trading Down 20.5 %

RMTI opened at $1.40 on Friday. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The firm has a market cap of $45.25 million, a price-to-earnings ratio of -28.00 and a beta of 1.55. The business’s 50 day moving average is $1.86 and its two-hundred day moving average is $2.62. Rockwell Medical has a 52 week low of $1.33 and a 52 week high of $5.15.

Analyst Ratings Changes

RMTI has been the topic of several recent analyst reports. StockNews.com lowered shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 20th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Rockwell Medical in a research report on Monday, December 23rd.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.